Inhibition of the type I IGF receptor (IGF1R) has been the focus of numerous clinical trials. Two reports in this issue describe the results of phase I trials of an IGF1R tyrosine kinase inhibitor OSI-906. This commentary will describe the complex endocrine changes induced by these types of agents. See related articles by Jones et al., p. 693, and Puzanov et al., p. 701
Bibliographical notePublisher Copyright:
© -2014 American Association for Cancer Research.